Fed Completed Phase 1 Trials for Ondansetron (DB00904)

Also known as: FED

IndicationStatusPhase
DBCOND0052071 (Fed)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01578265Bioequivalence Study of Ondansetron Tablets USP 8 mg Under Fed ConditionTreatment